GSC
PLRX icon

Ground Swell Capital’s Pliant Therapeutics PLRX Stock Holding History

Ground Swell Capital’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,874
Closed -$13.8K – 210
2025
Q2 		$13.8K Buy
+11,874
New +$16.8K 0.02% 117

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Ground Swell Capital's PLRX Position: Q3 2025 in Review

Ground Swell Capital sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 11,874 shares — an estimated $13.8K sold.

Ground Swell Capital first reported a position in PLRX in Q2 2025 and held it in 1 quarter. The position peaked at $13.8K in Q2 2025. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

  • Ground Swell Capital reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ground Swell Capital sold 11,874 Pliant Therapeutics shares in Q3 2025, an estimated $13.8K.
  • Ground Swell Capital first reported a position in Pliant Therapeutics in Q2 2025 and held it in 1 quarter.
  • Ground Swell Capital's Pliant Therapeutics position peaked at $13.8K in Q2 2025.
  • 99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on Ground Swell Capital's 13F filing for Q3 2025, filed 6 Nov 2025.